Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

58.22 +1.43 (+2.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 381,347
Open 57.02
Bid (Size) 54.75 (1)
Ask (Size) 93.15 (2)
Prev. Close 56.79
Today's Range 56.34 - 58.64
52wk Range 37.82 - 79.40
Shares Outstanding 60,467,345
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Biotech Could Soon Go Parabolic, But Should You Buy It?
Its situation is neither as good nor as bad as it might seem at first glance. 
Via The Motley Fool
Blueprint Medicines Earns Higher Price Targets Post FDA Approval: Analysts Optimistic on Ayvakit's Future
Shares of Blueprint Medicines Corporation (NASDAQ: BPMC) after it received FDA approval for its Ayvakit (avapritinib) as the first, only treatment for  
Via Benzinga

Performance

YTD
+34.46%
+34.46%
1 Month
+3.54%
+3.54%
3 Month
+34.09%
+34.09%
6 Month
+16.00%
+16.00%
1 Year
+0.48%
+0.48%

More News

Read More
FDA OKs Blueprint Medicines' Blood Disorder Drug As First Treatment For SM Patients
Via Benzinga
Analyst Expectations for Blueprint Medicines's Future
Via Benzinga
Blueprint Medicines's Return On Capital Employed Overview
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Via Benzinga
16 Analysts Have This to Say About Blueprint Medicines
Via Benzinga
FDA Removes Partial Clinical Hold From Blueprint Medicines' Cancer Study
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Via Benzinga
Earnings Scheduled For February 16, 2023
Via Benzinga
Earnings Preview For Blueprint Medicines
Via Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Via InvestorPlace
Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients
Via Benzinga
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
Via Benzinga
FDA Slaps Partial Clinical Hold On Blueprint Medicines' Early-Stage Solid Tumor Study
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Via Benzinga
9 Analysts Have This to Say About Blueprint Medicines
Via Benzinga
Recap: Blueprint Medicines Q3 Earnings
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Blueprint Medicines's Return On Capital Employed Overview
Via Benzinga
Blueprint Medicines Stock Gets Price Target Cut Amid Lower Than Expected Ayvakit Uptake
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Via Benzinga
Uber To Rally Around 82%? Here Are 5 Other Price Target Changes For Wednesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.